|
LPP expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.1547999485303E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.31459998232009E-09 |
| Normal-vs-Stage2 |
1.05429999952555E-07 |
| Normal-vs-Stage3 |
1.75990000350623E-08 |
| Normal-vs-Stage4 |
9.61659973874873E-10 |
| Stage1-vs-Stage2 |
7.160200E-01 |
| Stage1-vs-Stage3 |
9.919000E-01 |
| Stage1-vs-Stage4 |
2.007000E-01 |
| Stage2-vs-Stage3 |
7.679400E-01 |
| Stage2-vs-Stage4 |
2.145000E-01 |
| Stage3-vs-Stage4 |
3.191200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.83909995302656E-09 |
| Normal-vs-AfricanAmerican |
5.32259999963536E-07 |
| Normal-vs-Asian |
9.64629487398838E-11 |
| Caucasian-vs-AfricanAmerican |
8.878800E-01 |
| Caucasian-vs-Asian |
1.509900E-02 |
| AfricanAmerican-vs-Asian |
8.436400E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.76140005201131E-09 |
| Normal-vs-Female |
5.29260002490872E-09 |
| Male-vs-Female |
7.463200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
9.92600002192034E-09 |
| Normal-vs-Age(41-60Yrs) |
6.46639963797213E-10 |
| Normal-vs-Age(61-80Yrs) |
1.28930000009575E-07 |
| Normal-vs-Age(81-100Yrs) |
2.301800E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.547190E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.419400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.710000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.240000E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.774800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.969600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.366200E-01 |
| Classical-VS-Follicular |
2.609400E-01 |
| Classical-VS-Other |
1.899140E-03 |
| Classical-VS-Normal |
8.44750003281547E-09 |
| Tall-VS-Follicular |
2.225200E-01 |
| Tall-VS-Other |
9.990100E-02 |
| Tall-VS-Normal |
3.38020000001382E-06 |
| Follicular-VS-Other |
3.980300E-04 |
| Follicular-VS-Normal |
3.68030000030828E-07 |
| Other-VS-Normal |
6.59770016397943E-11 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.10030004499373E-09 |
| Normal-vs-N1 |
1.97499999687878E-08 |
| N0-vs-N1 |
7.827800E-01 |
|
|
